OBJECTIVE: To evaluate if the measurement of survivin in the blood of patients with rheumatoid arthritis (RA) undergoing infliximab treatment has predictive value for treatment response. METHODS: The study included 87 consecutive RA patients (age 24-89 years, disease duration 18-526 months) treated with regular infusions of influximab. Survivin levels were measured by enzyme-linked immunosorbent assay and evaluated in relation to the total dose of infliximab, disease activity (DAS28), response to infliximab treatment (change in DAS28 >1.2), and radiographic damage (vdH-Sharp score). RESULTS: Thirty-seven percent of patients were survivin-positive (survivin >0.9 ng/mL) and showed severe radiographic damage at the start of infliximab treatment compared with survivin-negative (P = 0.027). Patients with high survivin levels were unlikely to respond to infliximab treatment (OR 4.02 [1.22-14.61], P = 0.022) and achieve remission (OR 4.32[1.01-30.11], P = 0.048) compared with patients with low survivin levels. CONCLUSIONS: High survivin levels are associated with severe radiographic damage at the start of treatment and a poor response to infliximab. Survivin measurement should be considered an additional tool for aiding the selection and follow-up of antirheumatic treatment.
OBJECTIVE: To evaluate if the measurement of survivin in the blood of patients with rheumatoid arthritis (RA) undergoing infliximab treatment has predictive value for treatment response. METHODS: The study included 87 consecutive RApatients (age 24-89 years, disease duration 18-526 months) treated with regular infusions of influximab. Survivin levels were measured by enzyme-linked immunosorbent assay and evaluated in relation to the total dose of infliximab, disease activity (DAS28), response to infliximab treatment (change in DAS28 >1.2), and radiographic damage (vdH-Sharp score). RESULTS: Thirty-seven percent of patients were survivin-positive (survivin >0.9 ng/mL) and showed severe radiographic damage at the start of infliximab treatment compared with survivin-negative (P = 0.027). Patients with high survivin levels were unlikely to respond to infliximab treatment (OR 4.02 [1.22-14.61], P = 0.022) and achieve remission (OR 4.32[1.01-30.11], P = 0.048) compared with patients with low survivin levels. CONCLUSIONS: High survivin levels are associated with severe radiographic damage at the start of treatment and a poor response to infliximab. Survivin measurement should be considered an additional tool for aiding the selection and follow-up of antirheumatic treatment.
Authors: Too Chun-Lai; Shahnaz Murad; Malin C Erlandsson; Heselynn Hussein; Wahinuddin Sulaiman; Jasbir S Dhaliwal; Maria I Bokarewa Journal: Medicine (Baltimore) Date: 2015-01 Impact factor: 1.889
Authors: Minna Turkkila; Karin M E Andersson; Sylvie Amu; Mikael Brisslert; Malin C Erlandsson; Sofia Silfverswärd; Maria I Bokarewa Journal: Arthritis Res Ther Date: 2015-07-10 Impact factor: 5.156
Authors: Sofia E M Andersson; Mattias N D Svensson; Malin C Erlandsson; Mats Dehlin; Karin M E Andersson; Maria I Bokarewa Journal: PLoS One Date: 2012-10-17 Impact factor: 3.240
Authors: Anak A S S K Dharmapatni; Melissa D Cantley; Victor Marino; Egon Perilli; Tania N Crotti; Malcolm D Smith; David R Haynes Journal: Mediators Inflamm Date: 2015-08-04 Impact factor: 4.711
Authors: Björn Svensson; Ingiäld Hafström; Malin C Erlandsson; Kristina Forslind; Maria I Bokarewa Journal: Arthritis Res Ther Date: 2014-01-16 Impact factor: 5.156
Authors: Linda L Kusner; Michael J Ciesielski; Alexander Marx; Henry J Kaminski; Robert A Fenstermaker Journal: PLoS One Date: 2014-07-22 Impact factor: 3.240
Authors: Karin M E Andersson; Mikael Brisslert; Nicola Filluelo Cavallini; Mattias N D Svensson; Amanda Welin; Malin C Erlandsson; Michael J Ciesielski; Gergely Katona; Maria I Bokarewa Journal: Oncotarget Date: 2015-08-21